Shuangcheng Pharmaceutical: There is uncertainty about whether the major asset restructuring can be successfully implemented

On October 17th, Jin10 Data reported that Shuangcheng Pharmaceutical announced a major asset restructuring. The company plans to purchase 100% of Aura shares held by 25 counterparties such as Aura Investment and WinAiming through issuance of shares and cash payment, and plans to raise matching funds through issuance of shares to no more than 35 specific investors. As of the date of this announcement, the audit and evaluation work of this transaction has not been completed, and the specific transaction price of this transaction has not been determined. The necessary internal decision-making procedures need to be completed for this restructuring, and it can only be officially implemented after approval by the competent regulatory authorities. The success of the final implementation is uncertain. Please follow up on subsequent announcements and pay attention to investment risks.